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Abstract
We previously described selective hypermethylation of the 5'-long terminal repeat (LTR) of HTLV-
1 provirus in vivo and in vitro. This prompted us to analyze CpG methylation of the two LTRs of the
HIV provirus in chronically infected cell lines. The results demonstrate selective hypermethylation
of the 5' LTR of the HIV provirus in ACH-2 cells. Moreover, induction of viral gene expression by
TNF-α resulted in demethylation of the 5'-LTR. These results suggest that selective epigenetic
modification of the 5'LTR of the HIV-1 provirus may be an important mechanism by which proviral
activity is suppressed.
Findings
With the use of highly active anti-retroviral therapy
(HAART) for HIV-infected individuals, greater control of
viral replication is now possible. The widespread use of
HAART has led to a substantial decline in the incidence of
acquired immunodeficiency syndrome (AIDS) and AIDS-
related mortality [1-6]. This development has led to con-
siderable optimism [7], but complete eradication of HIV
from an infected individual is difficult to achieve because
there are latently infected resting CD4+ T cells carrying
replication-competent HIV resistant to HAART [8-11]. A
better understanding of mechanisms underlying latency
and reactivation of HIV might yield information on how
to overcome the resistance of latent HIV to treatment, and
this would contribute to the goal of containment or purg-
ing of HIV.
Epigenetic control is thought to be involved in latent
infection of HIV. Epigenetic mechanisms result in the her-
itable silencing of genes without a change in their coding
sequence. Three systems, including DNA methylation,
RNA-associated silencing and histone modification, are
used to initiate and sustain epigenetic silencing [12]. His-
tone deacetylation is important for quiescence of HIV
gene expression in infected resting CD4+ T lymphocytes.
Blockade of histone deacetylase (HDAC) activity can stim-
ulate the release of virus from latently infected CD4+ T-
cells in vitro and, in combination with enfuvirtde, reduces
the pool of CD4+ T-cells in vivo[13-15].
CpG methylation has been implicated in silencing of the
integrated provirus genome [16,17] as well as in regula-
tion of many imprinted genes [18]. Demethylation
induced by an inhibitor of DNA methyltransferase, 5-Aza-
cytidine (5-AzaC), was shown to reactivate a latent provi-
rus [19]. In vitro studies have shown that DNA
methylation suppresses the promoter activity of the HIV-
1 long terminal repeat (LTR) [20-23], suggesting that CpG
methylation may play an important role in viral latency in
vivo.
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Cytokines such as TNF-α induce HIV gene expression in
chronically infected T cell lines [24,25], as well as in
latently infected lymphocytes in vivo [26,27]. Using
chronically infected T cell lines, we investigated CpG
methylation of provirus LTR and its relationship to regu-
latory mechanisms that reactivate the latent HIV provirus.
We found that CpG sites in the 5'-LTR are selectively
hypermethylated, and that TNF-α-induced reactivation is
associated with demethylation of the 5' LTR. Our observa-
tions provide clues to the mechanism of signal-mediated
demethylation and reactivation of latent HIV.
To evaluate the effects of CpG methylation on the pro-
moter activity of the HIV LTR, we first tested the effects of
in vitro CpG methylation of HIV LTR-luciferase constructs
on activity in transient transfection assays. When trans-
fected into Jurkat cells, the HIV LTR-Luc plasmid showed
significant basal levels of luciferase activities, whereas SssI
methylase-treated HIV LTR-Luc plasmid showed 100-fold
lower luciferase activities (Fig. 1A). We also found that
CpG methylation suppressed the LTR's response to acti-
vating agents such as HIV Tat or TNF-α. The small
responses we observed might be due to incomplete meth-
ylation of CpG during SssI methylase treatment, since
bisulfite-sequencing analysis of the SssI-treated plasmid
detected some unmethylated copies (data not shown).
Thus, CpG methylation of the HIV LTR suppresses both
basal promoter activity and responses to activating stim-
uli; this confirms results of earlier studies [20-23].
We next asked if LTRs of integrated proviruses were meth-
ylated. Using bisulfite genomic sequencing [28], we ana-
lyzed methylation of each CpG site in the U3 region of the
HIV-1 LTR in chronically infected cell lines. Primers used
for amplification of the modified sense strand are: LTR
forward primer (F-3): 5'-TTTGTTATATTTTGTGAGTTTG-
TAT-3' (nucleotide position: 200 to 224, 9285 to 9309),
reverse primer (R-1), 5'-CAAAAAACTCCCAAACT-
CAAATCTA-3' (nucleotide position: 496 to 472, 9581 to
9557). Amplified products were cloned by the TA method
followed by sequence analysis using an automated
sequencer (Amersham Bioscience, Gene Rapid). The
results showed various levels of CpG methylation in Molt
20-2, ACH-2 and U-1 cell lines, which correlated inversely
with basal levels of viral gene expression (Fig. 1B and C).
We then asked if TNF-α-induced HIV-1 gene expression in
ACH-2 is associated with changes in CpG methylation in
the LTR. TNF-α stimulation induced activation of viral
gene expression after 24 hours (Fig. 2A). We used bisulfite
genomic sequencing, to characterize the methylation sta-
tus of nine CpG sites located in the U3 region of the HIV
LTR, before and after TNF-α treatment. Bisulfite sequenc-
ing of the provirus before TNF-α treatment revealed a fea-
ture that is typical of CpG methylation (Fig. 2). The 10
Promoter activity and CpG methylation of HIV LTR Figure 1
Promoter activity and CpG methylation of HIV LTR. A. Suppression of HIV LTR promoter activity by CpG methylation in vitro. 
HIV LTR-Luc plasmid, with or without in vitro methylation by SssI methylase, was transiently transfected into Jurkat cells with 
pRL-tk-Luc plasmid. Representative results of triplicate experiments are presented with standard deviation. Relative luciferase 
activity was determined by dividing the activity of firefly luciferase by that of renilla luciferase. Three independent experiments 
gave almost identical results. B. Northern blot analysis of HIV mRNA. Expression of HIV mRNA was detected using HIV LTR 
probe (upper panel). Molt20-2 is a gift from Prof. T Shiota (Osaka University) and derived form Molt4 infected by HIV Lai. 
Lower panel, photograph of ethidium bromide stained samples. C. Results of CpG methylation analysis of integrated HIV pro-
virus LTRs of chronically infected cells lines. Single line represents the results of one plasmid clone analyzed. Upper panel, 
Schematic map of the CpG sites in the U3 region of HIV-1 IIIB LTR. Closed and open circles indicate methylated and unmeth-
ylated CpG sites, respectively.
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plasmid clones analyzed displayed either hypermethyla-
tion or hypomethylation. Among five hypermethylated
clones, three were methylated at all CpGs, and one had 7
out of 9 sites methylated. In DNA extracted from cells after
24 hours of TNF-α treatment, no alleles were completely
methylated. Five of 10 sequenced plasmid clones dis-
played some CpG methylation, and the remaining five
clones were completely unmethylated. After 48 hours of
TNF-α treatment, there was a clear trend toward demeth-
ylation. Eight clones were completely unmethylated, and
one had only one methylated CpG (Fig. 2B).
Taken together, the results shown in Fig. 2 can be summa-
rized as follows: 1) at least half of the analyzed clones
were unmethylated before and after TNF-α treatment, 2)
the levels of CpG methylation in the remaining clones
showed a clear decrease that was related to the duration of
TNF-α treatment. The primers we used can amplify both
5' and 3' LTR sequences, and methylation of only half of
the amplified clones suggests that methylation may affect
only the 5' or the 3' LTR, as we found previously in studies
of the HTLV-1 provirus [29]. On the other hand, the
response to TNF-α provides evidence of cytokine receptor
signal-mediated demethylation of the provirus LTR. The
mechanism by which LTR is demethylated remains to be
elucidated. However, our previous observation in HIV
transgenic mice suggested a passive mechanism for
demethylation of HIV LTR which depends on DNA repli-
cation as is supposed for demethylation of cellular
genes[30].
To examine the possibility that hypermethylation is selec-
tive for the 5' LTR of the HIV provirus, we first identified
the flanking genomic sequences of the integrated provirus
in ACH-2 cells using the inverse polymerase chain reac-
tion (I-PCR) [29]. Genomic DNA was digested with a
restriction enzyme TthHB8I, followed by self-ligation for
12 hrs. Ligated DNA was subjected to PCR amplification
using the following primers: forward primer (iHIV-2): 5'-
TTCATCACGTGGCCCGAGAGCTGCATCCGGAGTAC-3'
(nucleotide position: 283 to 317), reverse primer (iHIV-
1): 5'-CCTTGTGTGTGGTAGATCCACAGATCAAGGATA-
3' (nucleotide position: 67 to 37). Agarose gel electro-
phoresis of the PCR products showed two amplified
bands with sizes of about 300 bp and 1,2 kbp. These
bands appear to correspond to those from 5'- and 3'-
flanking sequences, since ACH-2 cells contain a single
copy of integrated HIV provirus per cell [31]. Both PCR
products were subcloned using pGEMT-easy (Promega,
Madison, Wisconsin) and the nucleotide sequences were
determined. The 1.2 kbp PCR product was shown to con-
tain the 5'-LTR sequence, and the 300 bp product that of
3'-LTR. NCBI human genomic blast program analysis of
the flanking sequences showed that the sequence of the
1.2 kbp fragment corresponds to that of Chromosome 7,
located at 7p15 (Fig.3B). We also identified the 5'-flank-
ing sequences contained the L1 family repetitive
sequences (Fig.3B bold italic).
We used the flanking sequences to selectively characterize
the CpG methylation status of the 5' LTR, preparing a for-
In vitro induction of HIV gene expression in ACH-2 cells, and  demethylation of CpGs in the LTRs Figure 2
In vitro induction of HIV gene expression in ACH-2 cells, and 
demethylation of CpGs in the LTRs. A. Induction of HIV 
mRNA in ACH-2 cell line by TNF-α. Two micrograms of 
poly (A)+ RNA was analyzed by northern blotting. B. CpG 
demethylation after HIV induction by TNF-α. Upper panel, 
Schematic map of the CpG sites in the U3 region of HIV-1 
IIIB LTR. The lower panel, results of bisulfite genomic 
sequencing. Cells are harvested at the time points indicated 
on the left. No, cells without TNF-α treatment. Each line 
represents a result of single plasmid clone. Closed and open 
circles indicate methylated and unmethylated CpG sites, 
respectively.
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ward primer located in the 5' flanking sequence. For anal-
ysis of the 3' LTR, we used a forward primer located in the
nef region. The primers used are follows: 5' flanking for-
ward primer (5'F-1) 5'-TATGAGGAATAGATTTTTT-
TATATG-3' (Fig.3), forward primer for 3' LTR (3'LTR-F1)
5'-TTATAAGGTAGTTGTAGATTTTAGT-3' (nucleotide
position 9036 to 9060), and the reverse primer R-1
(described above). The results clearly demonstrated selec-
tive hypermethylation of the 5' LTR, with almost complete
hypomethylation of the 3' LTR (Fig. 4), which was in
accordance with our previous findings with integrated
HTLV-1 provirus in vivo and in vitro [29].
In DNA from unstimulated ACH-2 cells, among 10 clones
derived from the 5' LTR, six showed methylation of all 9
CpG sites, and two had only two unmethylated CpGs,
although two clones showed complete hypomethylation
of the 9 CpG sites. In contrast, all 10 clones derived from
the 3' LTR were hypomethylated, with only one methyl-
ated site in one clone. The 3' LTR did not show any
changes in methylation on TNF-α stimulation (Fig. 4).
TNF-α stimulation resulted in increase in unmethylated
CpGs in the 5' LTR. After 24 hours of TNF-α stimulation,
only one clone out of 10 remained completely methyl-
ated, and most clones had one to five unmethylated sites,
while one was completely unmethylated. After 48 hours
of stimulation, none of the sequenced clones were com-
pletely methylated (Fig. 4). Demethylated CpGs appeared
to cluster in the first 5 CpG sites (reading 5' to 3'), with
higher frequency at the 5th site. Three of 10 clones from
unstimulated ACH-2 cells had an unmethylated 5th CpG
site, and 6 clones each had unmethylated 5th CpG site
after 24 and 48 hours of stimulation. Furthermore, the
number of unmethylated CpGs in the first 5 sites
increased with the time of TNF-α stimulation. Before
stimulation, 12 (24%) of total 50 sites were unmethyl-
ated, whereas after stimulation 22 (44%) and 26 (52%)
sites were unmethylated at 24 and 48 hours respectively.
On the other hand, in the cluster of 4 sites at the 3 end of
the cluster, among a total of 40 sites analyzed 8 (20%)
were unmethylated in unstimulated cells, and after TNF-α
stimulation 6 (15%) and 17 (42.5%) sites were unmeth-
ylated at 24 and 48 hours respectively. Taken together,
demethylation induced by TNF-α showed a tendency to
cluster in the CpG sites located at the 5' end. Furthermore,
the 5th CpG site may be a hot spot for demethylation in
the TNF-α stimulated cells.
Nevertheless, our results demonstrate that in the setting of
full reactivation of viral gene expression by TNF-α stimu-
lation, the provirus LTR showed only a partial demethyla-
tion at scattered sites (Fig. 4). This observation is
inconsistent with the widely accepted idea that promoter
activity is regulated by the density of CpG methylation
[22,32,33]. Our results may provide support for the idea
that demethylation of a specific CpG site plays an impor-
tant role in promoter activity of the HIV LTR, which we
have previously reported using HIV transgenic mice [30].
It is also consistent with the notion that CpG methylation
of specific sites plays an important role in controlling the
promoter activities of EBV and imprinted genes [34-38].
Differential methylation of two LTRs located within 10
kbp of each other in the provirus genome, which we pre-
viously reported in the human retrovirus HTLV-1 [29],
may suggest the presence of an unknown mechanism of
methylation targeting that discriminates the 5'from the 3'
LTR. The difference may depend on chemical modifica-
tion of histone H3, such as lysine 9 (K9) methylation,
since repression of gene expression mediated by histone
Identification of the flanking genomic sequence of the inte- grated HIV provirus in ACH-2 cells by the inverse PCR Figure 3
Identification of the flanking genomic sequence of the inte-
grated HIV provirus in ACH-2 cells by the inverse PCR. A. A 
schematic chart of the inverse PCR procedure. B. Host 
genomic sequence flanking 5'-LTR. Underlined sequence indi-
cates TthHB8I restriction enzyme site. Double underline 
indicates the sequence used for the sense primer in 5'-LTR 
specific methylation analysis. Bold italic indicates the L1 fam-
ily sequences. Right panel shows a schematic presentation of 
the chromosomal location of the integration site of HIV-1 in 
ACH-2 cells determined by the NCBI human genomic blast 
program. Arrow indicates the region of integration.
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TCGACCTTTG GTTGCATTAA TCAAAATGCA GTGTTCCAGG CAGATCACAC 
TGAAAGCACT GTGTCGGATT CTGGAAGAAT GCTGTTAAGA GAAACCATGA 
CAATAGTGAC CAAAAAAAAA AAAAATAGAT CATGACAAAC TTAAAAGGAG 
TCAGAGTAGT CCACCAGAAT GATCAGAGGA ATTTGAGCCT TCCCACTTGA 
CGAACATTTC AAGGAATAGA AAATGCTTTG ATTTGAGAAG GAACAACTTG 
TTTTAAAATC TTAGGAGACC AGGAATGATT TGTCTTTATT GTCCCGTTAC 
GTAACAGTTG CATACTTCAT CTGTATTTGT GGTACTAAAT GTTGAAAAGA 
TATTAGACTT AACTCTACAA ACTGGTAGCA GCAGAACTGG AACTAGACTT 
GGAAGATATA AGAAGATTGA TTTCAGCATG AGAAATGAAA AGCCTGTCTA 
GCAATTAAGA GTTTTCTGGC AATGGAATAA GCTTCCCTGG GAGAATGAGC 
TTACTGACAT GTTAGAAGCT GACCCAGGCA GGGAAGAAGG TGACTTAGGA 
ATATTATAGG GGTATTTTTA GGTATCAGAT GAAGAGTTAG GCTTTTTTTT 
CTTTTCGTTT CTTTCTTTCT GTTTTTAGTG GCTGTTTGCA TAATTGTAAT 
GGGTTAGAGA GTCTAAGGGC CCTTTATACT GAGATGCTAT GATTATAGGT 
GTTTTCTACA TAAAGCAGGC TAATCTGTAT ATGACACTTG CCATAACAAA 
GATTTTCTCT CTTGTTCACT AAGTAGCATC TTCAGTATGT AGAAAATTCA 
AACTACAAAC AAATTTTAAA AATGGGGTTG CTCTAATTCA TTTTACTGCA 
ATCAGAGAAA GGATTATGCT TCCATAGGTT GGGTTGAGTT TTTATGTGTA 
GAATTAGGAA AGGTTTATAG CTAGTTTCCT TTCATTACCT TACTAACATA 
TTTAAGCTAA GTCTGGGTTT GGGAGGACTG GGAAACTCAG TAAGAACATG 
CATATCACAT TTTGAGACAT GAGGTATACA TTCATTAGTG ATGAACTTCA 
ATCTCTAAAA TTTAAATCCA AATATGAGGA ACAGATTTTC TCACATGGAA 
GAATGTTTTG TAAT...LTRRetrovirology 2006, 3:69 http://www.retrovirology.com/content/3/1/69
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H3 K9 methylation is thought to be stabilized by DNA
methylation[39].
Previous studies in vitro suggested CpG methylation of the
HIV-1 LTR as a mechanism to maintain HIV-1 latency [20-
23,40,41]. However, no information is available as to the
CpG methylation status of the HIV provirus in the reser-
voir pool in vivo, because extremely low copy numbers of
HIV provirus make it infeasible to directly analyze CpG
methylation with bisulfite genomic sequencing. In spite
of the widely accepted idea that CpG methylation is
involved in suppression of HIV gene expression and
latency, a recent report suggested that proviral DNA meth-
ylation may not be involved in transcriptional suppres-
sion of integrated HIV provirus [42]. However, this report
used an artificial system in which provirus methylation
was analyzed on a defective HIV genome or a vector hav-
ing only HIV LTR as the promoter. Because we lack infor-
mation on the state of the latent HIV provirus in vivo, the
notion remains to be examined.
Decipherment of the mechanisms for reactivation of
latently infected HIV in the reservoir pool will provide the
basis for designing treatment strategies for containment or
purging of HIV. Thus our observations of 5' LTR selective
methylation in ACH-2 cells, and signal-induced demeth-
ylation of HIV provirus in the transgenic mice model and
latently infected cell lines [30], provide information that
will be useful in future investigations.
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Selective analysis of CpG methylation of two LTRs Figure 4
Selective analysis of CpG methylation of two LTRs. Methylation of CpG sites in each plasmid clone is displayed. Closed and 
open circles indicate methylated and unmethylated CpG sites, respectively. TNF-α treated cells are harvested at the time 
points indicated in the middle. (-), ACH-2 cells harvested before TNF-α treatment.
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